The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience
The optimal choice of salvage therapy for patients with relapsed/refractory non-Hodgkin lymphoma or Hodgkin lymphoma remains controversial. In this study, we aimed to share our experience in relapsed/refractory lymphoma patients who received GDP/R-GDP as salvage chemotherapy in our center. Data of 4...
Gespeichert in:
| Veröffentlicht in: | Journal of oncology pharmacy practice 2020-12, Vol.26 (8), p.1857-1863, Article 1857 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1863 |
|---|---|
| container_issue | 8 |
| container_start_page | 1857 |
| container_title | Journal of oncology pharmacy practice |
| container_volume | 26 |
| creator | Batgi, Hikmettullah Merdin, Alparslan Dal, Mehmet Sinan Kızıl Çakar, Merih Yıldız, Jale Başçı, Semih Uncu Ulu, Bahar Yiğenoğlu, Tuğçe Nur Darçın, Tahir Şahin, Derya Bakırtaş, Mehmet Tetik, Ayşegül İskender, Dicle Altuntaş, Fevzi |
| description | The optimal choice of salvage therapy for patients with relapsed/refractory non-Hodgkin lymphoma or Hodgkin lymphoma remains controversial. In this study, we aimed to share our experience in relapsed/refractory lymphoma patients who received GDP/R-GDP as salvage chemotherapy in our center. Data of 47 relapsed/refractory Hodgkin lymphoma and non-Hodgkin lymphoma patients who received GDP or R-GDP as salvage chemotherapy in our center between July 2014 and October 2017 were retrospectively evaluated. Non-Hodgkin lymphoma and Hodgkin lymphoma patients were divided into two groups as primary refractory and relapsed. The one-year overall survival was 100% (for relapsed) and 36.9% (for refractory) in the non-Hodgkin lymphoma groups, and 82.5% (for relapsed) and 80% (for refractory) in the Hodgkin lymphoma group. The one-year progression-free survival (PFS) was 72.7% (for relapsed) and 38.5% (for refractory) in patients with NHL, and 41% (for relapsed) and 18.2% (for refractory) in patients with HL. GDP/R-GDP seems to be a well-tolerated out-patient salvage regimen for relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma. Although proven efficacy, negative toxicity profile, and ease of administration, the application of gemcitabine-based therapy for patients with primary refractory non-Hodgkin lymphoma and Hodgkin lymphoma provided limited success. |
| doi_str_mv | 10.1177/1078155220905654 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2467325284</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1078155220905654</sage_id><sourcerecordid>2467325284</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-ea13a3ca92b72d817aeff201dc7165d65d88eeda099aff7250e4ef902a7211933</originalsourceid><addsrcrecordid>eNp9UMtKxDAUDaL4GN27koBbq0naNK07GXzBoBsFd-VOejsT6cskAzPf4E-bOqOCoBC4OZxHbg4hx5ydc67UBWcq41IKwXImU5lskX2eKBWxXLxsh3ugo4HfIwfOvTLGMiWyXbIXB0MmZbxP3p_mSLGqUHvaVXSGjTYepqbFM1riEhr0c3DdAKEtqTaur8Gbluo5Np2fo4V-RQO2WEPvsLywWFnQvrMr-nA3-XSF0QcTtt5d0ivqTDurkeqA0VJc9mgDp_GQ7FRQOzzazBF5vrl-Gt9Fk8fb-_HVJNJxKn2EwGOINeRiqkSZcQVhf8F4qRVPZRlOliGWwPIcqkoJyTDBKmcClOA8j-MROV3n9rZ7W6DzxWu3sG14shBJqmIhRZYEFVurtO2cC78qemsasKuCs2Jov_jdfrCcbIIX0wbLb8NX3UGQ_soc2vama70FU_-XHK2NDmb4s-6f-g_y_56M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2467325284</pqid></control><display><type>article</type><title>The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><creator>Batgi, Hikmettullah ; Merdin, Alparslan ; Dal, Mehmet Sinan ; Kızıl Çakar, Merih ; Yıldız, Jale ; Başçı, Semih ; Uncu Ulu, Bahar ; Yiğenoğlu, Tuğçe Nur ; Darçın, Tahir ; Şahin, Derya ; Bakırtaş, Mehmet ; Tetik, Ayşegül ; İskender, Dicle ; Altuntaş, Fevzi</creator><creatorcontrib>Batgi, Hikmettullah ; Merdin, Alparslan ; Dal, Mehmet Sinan ; Kızıl Çakar, Merih ; Yıldız, Jale ; Başçı, Semih ; Uncu Ulu, Bahar ; Yiğenoğlu, Tuğçe Nur ; Darçın, Tahir ; Şahin, Derya ; Bakırtaş, Mehmet ; Tetik, Ayşegül ; İskender, Dicle ; Altuntaş, Fevzi</creatorcontrib><description>The optimal choice of salvage therapy for patients with relapsed/refractory non-Hodgkin lymphoma or Hodgkin lymphoma remains controversial. In this study, we aimed to share our experience in relapsed/refractory lymphoma patients who received GDP/R-GDP as salvage chemotherapy in our center. Data of 47 relapsed/refractory Hodgkin lymphoma and non-Hodgkin lymphoma patients who received GDP or R-GDP as salvage chemotherapy in our center between July 2014 and October 2017 were retrospectively evaluated. Non-Hodgkin lymphoma and Hodgkin lymphoma patients were divided into two groups as primary refractory and relapsed. The one-year overall survival was 100% (for relapsed) and 36.9% (for refractory) in the non-Hodgkin lymphoma groups, and 82.5% (for relapsed) and 80% (for refractory) in the Hodgkin lymphoma group. The one-year progression-free survival (PFS) was 72.7% (for relapsed) and 38.5% (for refractory) in patients with NHL, and 41% (for relapsed) and 18.2% (for refractory) in patients with HL. GDP/R-GDP seems to be a well-tolerated out-patient salvage regimen for relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma. Although proven efficacy, negative toxicity profile, and ease of administration, the application of gemcitabine-based therapy for patients with primary refractory non-Hodgkin lymphoma and Hodgkin lymphoma provided limited success.</description><identifier>ISSN: 1078-1552</identifier><identifier>EISSN: 1477-092X</identifier><identifier>DOI: 10.1177/1078155220905654</identifier><identifier>PMID: 32098553</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Chemotherapy ; Cisplatin ; Cisplatin - administration & dosage ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; Dexamethasone ; Dexamethasone - administration & dosage ; Female ; Gemcitabine ; Hodgkin Disease - drug therapy ; Humans ; Lymphoma ; Lymphoma, Non-Hodgkin - drug therapy ; Male ; Middle Aged ; Neoplasm Recurrence, Local - drug therapy ; Non-Hodgkin's lymphoma ; Retrospective Studies ; Salvage Therapy - adverse effects ; Salvage Therapy - methods ; Steroids ; Survival ; Toxicity ; Young Adult</subject><ispartof>Journal of oncology pharmacy practice, 2020-12, Vol.26 (8), p.1857-1863, Article 1857</ispartof><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-ea13a3ca92b72d817aeff201dc7165d65d88eeda099aff7250e4ef902a7211933</citedby><cites>FETCH-LOGICAL-c365t-ea13a3ca92b72d817aeff201dc7165d65d88eeda099aff7250e4ef902a7211933</cites><orcidid>0000-0002-4204-7515 ; 0000-0002-5993-1403</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1078155220905654$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1078155220905654$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21817,27922,27923,43619,43620</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32098553$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Batgi, Hikmettullah</creatorcontrib><creatorcontrib>Merdin, Alparslan</creatorcontrib><creatorcontrib>Dal, Mehmet Sinan</creatorcontrib><creatorcontrib>Kızıl Çakar, Merih</creatorcontrib><creatorcontrib>Yıldız, Jale</creatorcontrib><creatorcontrib>Başçı, Semih</creatorcontrib><creatorcontrib>Uncu Ulu, Bahar</creatorcontrib><creatorcontrib>Yiğenoğlu, Tuğçe Nur</creatorcontrib><creatorcontrib>Darçın, Tahir</creatorcontrib><creatorcontrib>Şahin, Derya</creatorcontrib><creatorcontrib>Bakırtaş, Mehmet</creatorcontrib><creatorcontrib>Tetik, Ayşegül</creatorcontrib><creatorcontrib>İskender, Dicle</creatorcontrib><creatorcontrib>Altuntaş, Fevzi</creatorcontrib><title>The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience</title><title>Journal of oncology pharmacy practice</title><addtitle>J Oncol Pharm Pract</addtitle><description>The optimal choice of salvage therapy for patients with relapsed/refractory non-Hodgkin lymphoma or Hodgkin lymphoma remains controversial. In this study, we aimed to share our experience in relapsed/refractory lymphoma patients who received GDP/R-GDP as salvage chemotherapy in our center. Data of 47 relapsed/refractory Hodgkin lymphoma and non-Hodgkin lymphoma patients who received GDP or R-GDP as salvage chemotherapy in our center between July 2014 and October 2017 were retrospectively evaluated. Non-Hodgkin lymphoma and Hodgkin lymphoma patients were divided into two groups as primary refractory and relapsed. The one-year overall survival was 100% (for relapsed) and 36.9% (for refractory) in the non-Hodgkin lymphoma groups, and 82.5% (for relapsed) and 80% (for refractory) in the Hodgkin lymphoma group. The one-year progression-free survival (PFS) was 72.7% (for relapsed) and 38.5% (for refractory) in patients with NHL, and 41% (for relapsed) and 18.2% (for refractory) in patients with HL. GDP/R-GDP seems to be a well-tolerated out-patient salvage regimen for relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma. Although proven efficacy, negative toxicity profile, and ease of administration, the application of gemcitabine-based therapy for patients with primary refractory non-Hodgkin lymphoma and Hodgkin lymphoma provided limited success.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Chemotherapy</subject><subject>Cisplatin</subject><subject>Cisplatin - administration & dosage</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Dexamethasone</subject><subject>Dexamethasone - administration & dosage</subject><subject>Female</subject><subject>Gemcitabine</subject><subject>Hodgkin Disease - drug therapy</subject><subject>Humans</subject><subject>Lymphoma</subject><subject>Lymphoma, Non-Hodgkin - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Non-Hodgkin's lymphoma</subject><subject>Retrospective Studies</subject><subject>Salvage Therapy - adverse effects</subject><subject>Salvage Therapy - methods</subject><subject>Steroids</subject><subject>Survival</subject><subject>Toxicity</subject><subject>Young Adult</subject><issn>1078-1552</issn><issn>1477-092X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UMtKxDAUDaL4GN27koBbq0naNK07GXzBoBsFd-VOejsT6cskAzPf4E-bOqOCoBC4OZxHbg4hx5ydc67UBWcq41IKwXImU5lskX2eKBWxXLxsh3ugo4HfIwfOvTLGMiWyXbIXB0MmZbxP3p_mSLGqUHvaVXSGjTYepqbFM1riEhr0c3DdAKEtqTaur8Gbluo5Np2fo4V-RQO2WEPvsLywWFnQvrMr-nA3-XSF0QcTtt5d0ivqTDurkeqA0VJc9mgDp_GQ7FRQOzzazBF5vrl-Gt9Fk8fb-_HVJNJxKn2EwGOINeRiqkSZcQVhf8F4qRVPZRlOliGWwPIcqkoJyTDBKmcClOA8j-MROV3n9rZ7W6DzxWu3sG14shBJqmIhRZYEFVurtO2cC78qemsasKuCs2Jov_jdfrCcbIIX0wbLb8NX3UGQ_soc2vama70FU_-XHK2NDmb4s-6f-g_y_56M</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Batgi, Hikmettullah</creator><creator>Merdin, Alparslan</creator><creator>Dal, Mehmet Sinan</creator><creator>Kızıl Çakar, Merih</creator><creator>Yıldız, Jale</creator><creator>Başçı, Semih</creator><creator>Uncu Ulu, Bahar</creator><creator>Yiğenoğlu, Tuğçe Nur</creator><creator>Darçın, Tahir</creator><creator>Şahin, Derya</creator><creator>Bakırtaş, Mehmet</creator><creator>Tetik, Ayşegül</creator><creator>İskender, Dicle</creator><creator>Altuntaş, Fevzi</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><orcidid>https://orcid.org/0000-0002-4204-7515</orcidid><orcidid>https://orcid.org/0000-0002-5993-1403</orcidid></search><sort><creationdate>202012</creationdate><title>The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience</title><author>Batgi, Hikmettullah ; Merdin, Alparslan ; Dal, Mehmet Sinan ; Kızıl Çakar, Merih ; Yıldız, Jale ; Başçı, Semih ; Uncu Ulu, Bahar ; Yiğenoğlu, Tuğçe Nur ; Darçın, Tahir ; Şahin, Derya ; Bakırtaş, Mehmet ; Tetik, Ayşegül ; İskender, Dicle ; Altuntaş, Fevzi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-ea13a3ca92b72d817aeff201dc7165d65d88eeda099aff7250e4ef902a7211933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Chemotherapy</topic><topic>Cisplatin</topic><topic>Cisplatin - administration & dosage</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Dexamethasone</topic><topic>Dexamethasone - administration & dosage</topic><topic>Female</topic><topic>Gemcitabine</topic><topic>Hodgkin Disease - drug therapy</topic><topic>Humans</topic><topic>Lymphoma</topic><topic>Lymphoma, Non-Hodgkin - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Non-Hodgkin's lymphoma</topic><topic>Retrospective Studies</topic><topic>Salvage Therapy - adverse effects</topic><topic>Salvage Therapy - methods</topic><topic>Steroids</topic><topic>Survival</topic><topic>Toxicity</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Batgi, Hikmettullah</creatorcontrib><creatorcontrib>Merdin, Alparslan</creatorcontrib><creatorcontrib>Dal, Mehmet Sinan</creatorcontrib><creatorcontrib>Kızıl Çakar, Merih</creatorcontrib><creatorcontrib>Yıldız, Jale</creatorcontrib><creatorcontrib>Başçı, Semih</creatorcontrib><creatorcontrib>Uncu Ulu, Bahar</creatorcontrib><creatorcontrib>Yiğenoğlu, Tuğçe Nur</creatorcontrib><creatorcontrib>Darçın, Tahir</creatorcontrib><creatorcontrib>Şahin, Derya</creatorcontrib><creatorcontrib>Bakırtaş, Mehmet</creatorcontrib><creatorcontrib>Tetik, Ayşegül</creatorcontrib><creatorcontrib>İskender, Dicle</creatorcontrib><creatorcontrib>Altuntaş, Fevzi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Journal of oncology pharmacy practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Batgi, Hikmettullah</au><au>Merdin, Alparslan</au><au>Dal, Mehmet Sinan</au><au>Kızıl Çakar, Merih</au><au>Yıldız, Jale</au><au>Başçı, Semih</au><au>Uncu Ulu, Bahar</au><au>Yiğenoğlu, Tuğçe Nur</au><au>Darçın, Tahir</au><au>Şahin, Derya</au><au>Bakırtaş, Mehmet</au><au>Tetik, Ayşegül</au><au>İskender, Dicle</au><au>Altuntaş, Fevzi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience</atitle><jtitle>Journal of oncology pharmacy practice</jtitle><addtitle>J Oncol Pharm Pract</addtitle><date>2020-12</date><risdate>2020</risdate><volume>26</volume><issue>8</issue><spage>1857</spage><epage>1863</epage><pages>1857-1863</pages><artnum>1857</artnum><issn>1078-1552</issn><eissn>1477-092X</eissn><abstract>The optimal choice of salvage therapy for patients with relapsed/refractory non-Hodgkin lymphoma or Hodgkin lymphoma remains controversial. In this study, we aimed to share our experience in relapsed/refractory lymphoma patients who received GDP/R-GDP as salvage chemotherapy in our center. Data of 47 relapsed/refractory Hodgkin lymphoma and non-Hodgkin lymphoma patients who received GDP or R-GDP as salvage chemotherapy in our center between July 2014 and October 2017 were retrospectively evaluated. Non-Hodgkin lymphoma and Hodgkin lymphoma patients were divided into two groups as primary refractory and relapsed. The one-year overall survival was 100% (for relapsed) and 36.9% (for refractory) in the non-Hodgkin lymphoma groups, and 82.5% (for relapsed) and 80% (for refractory) in the Hodgkin lymphoma group. The one-year progression-free survival (PFS) was 72.7% (for relapsed) and 38.5% (for refractory) in patients with NHL, and 41% (for relapsed) and 18.2% (for refractory) in patients with HL. GDP/R-GDP seems to be a well-tolerated out-patient salvage regimen for relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma. Although proven efficacy, negative toxicity profile, and ease of administration, the application of gemcitabine-based therapy for patients with primary refractory non-Hodgkin lymphoma and Hodgkin lymphoma provided limited success.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>32098553</pmid><doi>10.1177/1078155220905654</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-4204-7515</orcidid><orcidid>https://orcid.org/0000-0002-5993-1403</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-1552 |
| ispartof | Journal of oncology pharmacy practice, 2020-12, Vol.26 (8), p.1857-1863, Article 1857 |
| issn | 1078-1552 1477-092X |
| language | eng |
| recordid | cdi_proquest_journals_2467325284 |
| source | MEDLINE; SAGE Complete A-Z List |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Chemotherapy Cisplatin Cisplatin - administration & dosage Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Dexamethasone Dexamethasone - administration & dosage Female Gemcitabine Hodgkin Disease - drug therapy Humans Lymphoma Lymphoma, Non-Hodgkin - drug therapy Male Middle Aged Neoplasm Recurrence, Local - drug therapy Non-Hodgkin's lymphoma Retrospective Studies Salvage Therapy - adverse effects Salvage Therapy - methods Steroids Survival Toxicity Young Adult |
| title | The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T17%3A39%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20gemcitabine,%20dexamethasone,%20and%20cisplatin%20chemotherapy%20in%20relapsed/refractory%20NHL%20and%20HL%20patients:%20A%20single%20center%20experience&rft.jtitle=Journal%20of%20oncology%20pharmacy%20practice&rft.au=Batgi,%20Hikmettullah&rft.date=2020-12&rft.volume=26&rft.issue=8&rft.spage=1857&rft.epage=1863&rft.pages=1857-1863&rft.artnum=1857&rft.issn=1078-1552&rft.eissn=1477-092X&rft_id=info:doi/10.1177/1078155220905654&rft_dat=%3Cproquest_cross%3E2467325284%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2467325284&rft_id=info:pmid/32098553&rft_sage_id=10.1177_1078155220905654&rfr_iscdi=true |